POST-ADAPTIVE SURVIVAL MECHANISMS IN MYCOBACTERIUM TUBERCULOSIS: A COMPREHENSIVE REVIEW
DOI:
https://doi.org/10.22159/ajpcr.2026v19i4.57867Keywords:
Mycobacterium tuberculosis, Post-adaptation, PhoPR, Post-translational modifications, Metabolic reprogramming, Phenotypic drug tolerance, Persistence, Host stress adaptationAbstract
Mycobacterium tuberculosis (MTB) survives hostile host environments by activating complex post-adaptive survival mechanisms that enable long-term persistence and drug tolerance. Under conditions of nutrient deprivation, hypoxia, oxidative stress, and immune pressure, MTB activates metabolic reprogramming, cell wall remodeling, and regulatory networks. These responses contribute to phenotypic drug tolerance and complicate tuberculosis (TB) treatment outcomes. This review summarizes molecular, metabolic, and phenotypic post-adaptive mechanisms employed by MTB, with particular emphasis on post-translational modifications, stress-responsive pathways, and dormancy-associated processes. In addition, the clinical relevance of these adaptive strategies, including their impact on drug efficacy, treatment duration, and therapeutic failure, is critically discussed. A deeper understanding of post-adaptive survival mechanisms may facilitate the development of improved therapeutic strategies targeting persistent and drug-tolerant TB.
Downloads
References
1. Mandal M, Pires D, Azevedo-Pereira JM, Anes E. Host-directed therapies based on protease inhibitors to control Mycobacterium tuberculosis and HIV coinfection. Microorganisms. 2025;13(5):1040. doi: 10.3390/microorganisms13051040, PMID 40431213
2. Ehrt S, Schnappinger D. Mycobacterial survival strategies in the phagosome: Defence against host stresses. Cell Microbiol. 2009;11(8):1170-8. doi: 10.1111/j.1462-5822.2009.01335.x, PMID 19438516
3. Kumar R, Singh P, Kolloli A, Shi L, Bushkin Y, Tyagi S,. Immunometabolism of phagocytes during Mycobacterium tuberculosis infection. Front Mol Biosci. 2019;6:105. doi: 10.3389/ fmolb.2019.00105, PMID 31681793
4. Prosser G, Brandenburg J, Reiling N, Barry CE 3rd, Wilkinson RJ, Wilkinson KA. The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition. Microbes Infect. 2017;19(3):177-92. doi: 10.1016/j.micinf.2016.10.001, PMID 27780773
5. Eoh H, Liu R, Lim J, Lee JJ, Sell P. Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2022;12:958240. doi: 10.3389/fcimb.2022.958240, PMID 36072228
6. Quinonez CG, Lee JJ, Lim J, Odell M, Lawson CP, Anyogu A. The role of fatty acid metabolism in drug tolerance of Mycobacterium tuberculosis. mBio. 2022;13(1):e0355921. doi: 10.1128/mbio.03559- 21, PMID 35012349
7. Da Silva PE, Von Groll A, Martin A, Palomino JC. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol. 2011;63(1):1-9. doi: 10.1111/j.1574- 695X.2011.00831.x, PMID 21668514
8. Strong EJ, Lee S. Targeting autophagy as a strategy for developing new vaccines and host-directed therapeutics against mycobacteria. Front Microbiol. 2021;11:614313. doi: 10.3389/fmicb.2020.614313, PMID 33519771
9. Urbaniec J, Xu Y, Hu Y, Hingley-Wilson S, McFadden J. Phenotypic heterogeneity in persisters: A novel ‘hunker’ theory of persistence. FEMS Microbiol Rev. 2022;46(1):fuab042. doi: 10.1093/femsre/ fuab042, PMID 34355746
10. De Gaetano GV, Lentini G, Famà A, Coppolino F, Beninati C. Antimicrobial resistance: Two-component regulatory systems and multidrug efflux pumps. Antibiotics (Basel). 2023;12(6):965. doi: 10.3390/antibiotics12060965, PMID 37370284
11. Bussi C, Gutierrez MG. Mycobacterium tuberculosis infection of host cells in space and time. FEMS Microbiol Rev. 2019;43(4):341-61. doi: 10.1093/femsre/fuz006, PMID 30916769
12. Dechow SJ, Goyal R, Johnson BK, Haiderer ER, Abramovitch RB, Dechow SJ. Signaling and virulence in Mycobacterium tuberculosis. Infect Immun. 2025;93(3):e00005-25.
13. Herb M, Schramm M. Functions of ROS in macrophages and antimicrobial immunity. Antioxidants (Basel). 2021;10(2):313. doi: 10.3390/antiox10020313, PMID 33669824
14. Shastri MD, Shukla SD, Chong WC, Dua K, Peterson GM, Patel RP. Role of oxidative stress in the pathology and management of human tuberculosis. Oxid Med Cell Longev. 2018;2018:7695364. doi: 10.1155/2018/7695364, PMID 30405878
15. Nur MM. Elucidating the Role of Mycobacterial Resuscitation- Promoting Factors in Stress Response and Metal Acquisition [PhD Thesis]. Leicester University of Leicester; 2022.
16. Pei D, Chang S. Metabolic versatility of Mycobacterium tuberculosis during infection and dormancy. Pathogens. 2021;10(7):889.
17. Borah K, Xu Y, McFadden J. Dissecting host-pathogen interactions in TB using systems-based omic approaches. Front Cell Infect Microbiol. 2021;12:756359.
18. Choudhary E, Sharma R, Pal P, Agarwal N. Deciphering the proteomic landscape of Mycobacterium tuberculosis in response to acid and oxidative stresses. ACS Omega. 2022;7(30):26749-66. doi: 10.1021/ acsomega.2c03092, PMID 35936415
19. Dey B, Bishai WR. Crosstalk between Mycobacterium tuberculosis and the host cell. Semin Immunol. 2014;26(6):486-96. doi: 10.1016/j. smim.2014.09.002, PMID 25303934
20. Singha B, Murmu S, Nair T, Rawat RS, Sharma AK, Soni V. Metabolic rewiring of Mycobacterium tuberculosis upon drug treatment and antibiotics resistance. Metabolites. 2024;14(1):63. doi: 10.3390/ metabo14010063, PMID 38248866
21. Raffetseder J. Interplay of Human Macrophages and Mycobacterium tuberculosis Phenotypes [PhD Thesis]. Linköping: Linköping University; 2016. p. 87.
22. Singh PR, Goar H, Paul P, Mehta K, Bamniya B, Vijjamarri AK. Dual functioning by the PhoR sensor is a key determinant to Mycobacterium tuberculosis virulence. PLOS Genet. 2023;19(12):e1011070. doi: 10.1371/journal.pgen.1011070, PMID 38100394
23. Salgueiro-Toledo VC, Bertol J, Gutierrez C, Serrano-Mestre JL, Ferrer- Luzon N, Vázquez-Iniesta L. Maintenance of cell wall remodeling and vesicle production are connected in Mycobacterium tuberculosis. eLife. 2025;13:RP94982. doi: 10.7554/eLife.94982, PMID 39960848
24. Jacobo-Delgado YM, Rodríguez-Carlos A, Serrano CJ, Rivas- Santiago B. Mycobacterium tuberculosis cell-wall and antimicrobial peptides: A mission impossible? Front Immunol. 2023;14:1194923. doi: 10.3389/fimmu.2023.1194923, PMID 37266428
25. Schami A, Islam MN, Wall M, Hicks A, Meredith R, Kreiswirth B. Drug resistant Mycobacterium tuberculosis strains have altered cell envelope hydrophobicity that influences infection outcomes in human macrophages. Sci Rep. 2024;14(1):30840. doi: 10.1038/s41598-024- 81457-0, PMID 39730579
26. Forrellad MA, Klepp LI, Gioffré A, Sabio y García JS, Morbidoni HR, De La Paz Santangelo M. Virulence factors of the Mycobacterium tuberculosis complex. Virulence. 2013;4(1):3-66. doi: 10.4161/ viru.22329, PMID 23076359
27. Zschiedrich CP, Keidel V, Szurmant H. Molecular mechanisms of two-component signal transduction. J Mol Biol. 2016;428(19):3752-75. doi: 10.1016/j.jmb.2016.08.003, PMID 27519796
28. Goyal R, Das AK, Singh R, Singh PK, Korpole S, Sarkar D. Phosphorylation of PhoP protein plays direct regulatory role in lipid biosynthesis of Mycobacterium tuberculosis. J Biol Chem. 2011;286(52):45197-208. doi: 10.1074/jbc.M111.307447, PMID 22072719
29. Liu W, Wang Y, Zhao J, Zhang X, Li Z, Jia H. Secretory protein mutant library screen in Mycobacterium tuberculosis. Front Microbiol. 2025;16:12345.
30. Flentie K, Garner AL, Stallings CL. Mycobacterium tuberculosis transcription machinery: Ready to respond to host attacks. J Bacteriol. 2016;198(9):1360-73. doi: 10.1128/JB.00935-15, PMID 26883824
31. Bush MJ. The actinobacterial WhiB-like (Wbl) family of transcription factors. Mol Microbiol. 2018;110(5):663-76. doi: 10.1111/mmi.14117, PMID 30179278
32. Pisu D, Provvedi R, Espinosa DM, Payan JB, Boldrin F, Palù G, e% The alternative sigma factors SigE and SigB are involved in tolerance and persistence to antitubercular drugs. Antimicrob Agents Chemother. 2017;61(12):e01596-17. doi: 10.1128/AAC.01596-17, PMID 28993339
33. Üremiş N, Üremiş MM. Oxidative/nitrosative stress, apoptosis, and redox signaling: Key players in neurodegenerative diseases. J Biochem Mol Toxicol. 2025;39(1):e70133. doi: 10.1002/jbt.70133, PMID 39799559
34. Lee JH, Yoo JS, Kim Y, Kim JS, Lee EJ, Roe JH. The WBLC/ WHIB7 transcription factor controls intrinsic resistance to translation-targeting antibiotics by altering ribosome composition. mBio. 2020;11(2):e00625-20.
35. Sikora AE, Beyhan S, Bagdasarian M, Yildiz FH, Sandkvist M. Cell envelope perturbation induces oxidative stress and changes in iron homeostasis in Vibrio cholerae. J Bacteriol. 2009;191(17):5398-408. doi: 10.1128/JB.00092-09, PMID 19542276
36. Mehta M, Singh A. Mycobacterium tuberculosis WhiB3 maintains redox homeostasis and survival in response to reactive oxygen and nitrogen species. Free Radic Biol Med. 2019;131:50-8. doi: 10.1016/j. freeradbiomed.2018.11.032, PMID 30500421
37. Raman S, Song T, Puyang X, Bardarov S, Jacobs WR Jr., Husson RN. The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in Mycobacterium tuberculosis. J Bacteriol. 2001;183(20):6119-25. doi: 10.1128/JB.183.20.6119- 6125.2001, PMID 11567012
38. Stapleton M, Haq I, Hunt DM, Arnvig KB, Artymiuk PJ, Buxton RS. Mycobacterium tuberculosis cAMP receptor protein (Rv3676) differs from the Escherichia coli paradigm in its cAMP binding and DNA binding properties and transcription activation properties. J BiolChem. 2010;285(10):7016-27. doi: 10.1074/jbc.M109.047720, PMID 20028978
39. Budzik JM, Swaney DL, Jimenez-Morales D, Johnson JR, Garelis NE, Repasy T. Dynamic post-translational modification profiling of Mycobacterium tuberculosis-infected primary macrophages. eLife. 2020;9:e51461. doi: 10.7554/eLife.51461, PMID 31951200
40. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective. Antimicrob Agents Chemother. 2002;46(2):267-74. doi: 10.1128/AAC.46.2.267-274.2002, PMID 11796329
41. Caminero JA, Cayla JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnosis and treatment of drug-resistant tuberculosis. Arch Bronconeumol. 2017;53(9):501-9. doi: 10.1016/j. arbres.2017.02.006, PMID 28359606
42. Zeng J, Platig J, Cheng TY, Ahmed S, Skaf Y, Potluri LP. Protein kinases PknA and PknB independently and coordinately regulate essential Mycobacterium tuberculosis physiologies and antimicrobial susceptibility. PLoS Pathog. 2020;16(4):e1008452. doi: 10.1371/ journal.ppat.1008452, PMID 32255801
43. Je S, Quan H, Na Y, Cho SN, Kim BJ, Seok SH. An in vitro model of granuloma-like cell aggregates substantiates early host immune responses against Mycobacterium massiliense infection. Biol Open. 2016;5(8):1118-27. doi: 10.1242/bio.019315, PMID 27489303
44. Nandakumar S, Kannanganat S, Dobos KM, Lucas M, Spencer JS, Fang S. O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection. PLOS Pathog. 2013;9(10):e1003705. doi: 10.1371/journal.ppat.1003705, PMID 24130497
45. Von Rosen T, Keller LM, Weber-Ban E. Survival in hostile conditions: Pupylation and the proteasome in actinobacterial stress response pathways. Front Mol Biosci. 2021;8:685757. doi: 10.3389/ fmolb.2021.685757, PMID 34179091
46. Kim J, Song CH. Stress granules in infectious disease: Cellular principles and dynamic roles in immunity and organelles. Int J Mol Sci. 2024;25(23):12950. doi: 10.3390/ijms252312950, PMID 39684660
47. Singh KK, Athira PJ, Bhardwaj N, Singh DP, Watson U, Saini DK. Acetylation of response regulator protein MtrA in M. Tuberculosis regulates its repressor activity. Front Microbiol. 2021;11:516315.
48. Mashabela GT, De Wet TJ, Warner DF. Mycobacterium tuberculosis metabolism. Microbiol Spectr. 2019;7(4):1107-28. doi: 10.1128/ microbiolspec.GPP3-0067-2019, PMID 31350832
49. Fâcă AI, Udeanu DI, Arsene AL, Mahler B, Drăgănescu D, Apetroaei MM. Nutritional deficiencies and management in tuberculosis: Pharmacotherapeutic and clinical implications. Nutrients. 2025;17(11):1878. doi: 10.3390/nu17111878, PMID 40507146
50. Stephanie F, Tambunan US, Siahaan TJ. M. Tuberculosis transcription machinery: A review on the mycobacterial RNA polymerase and drug discovery efforts. Life (Basel). 2022;12(11):1774.
51. DiNardo AR, Rajapakshe K, Nishiguchi T, Grimm SL, Mtetwa G, Dlamini Q. DNA hypermethylation during tuberculosis dampens host immune responsiveness. J Clin Invest. 2020;130(6):3113-23. doi: 10.1172/JCI134622, PMID 32125282
52. Barandun J, Delley CL, Weber-Ban E. The pupylation pathway and its role in mycobacteria. BMC Biol. 2012;10:95. doi: 10.1186/1741-7007- 10-95, PMID 23198822
53. Barandun J, Damberger FF, Delley CL, Laederach J, Allain FH, Weber-Ban E. Prokaryotic ubiquitin-like protein remains intrinsically disordered when covalently attached to proteasomal target proteins. BMC Struct Biol. 2017;17(1):1. doi: 10.1186/s12900-017-0072-1, PMID 28143508
54. Festa RA, McAllister F, Pearce MJ, Mintseris J, Burns KE, Gygi SP. Prokaryotic ubiquitin-like protein (Pup) proteome of Mycobacterium tuberculosis [corrected]. PLOS One. 2010;5(1):e8589. doi: 10.1371/ journal.pone.0008589, PMID 20066036
55. Lin B, Qing X, Liao J, Znuo K. Role of protein glycosylation in host-pathogen interaction. Cells. 2020;9(9):2073.
56. Parbhoo T, Mouton JM, Sampson SL. Phenotypic adaptation of Mycobacterium tuberculosis to host-associated stressors that induce persister formation. Front Cell Infect Microbiol. 2022;12:956607. doi: 10.3389/fcimb.2022.956607, PMID 36237425
57. Wehenkel A, Bellinzoni M, Graña M, Duran R, Villarino A, Fernandez P. Mycobacterial Ser/Thr protein kinases and phosphatases: Physiological roles and therapeutic potential. Biochim Biophys Acta. 2008;1784(1):193-202. doi: 10.1016/j. bbapap.2007.08.006, PMID 17869195
58. Umar M, Afzal H, Murtaza A, Cheng LT. Lipoprotein signal peptide as adjuvants: Leveraging lipobox-driven TLR2 activation in modern vaccine design. Vaccines (Basel). 2025;13(1):36. doi: 10.3390/ vaccines13010036
59. Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA. Extreme drug tolerance of Mycobacterium tuberculosis in caseum. Antimicrob Agents Chemother. 2018;62(2):e02266-17. doi: 10.1128/ AAC.02266-17, PMID 29203492
60. Sarathy JP. Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis. PLoS Pathog. 2024;20(10):e1012595. doi: 10.1371/journal.ppat.1012595, PMID 39383167
61. Ju X, Li S, Froom R, Wang L, Lilic M, Delbeau M. Incomplete transcripts dominate the Mycobacterium tuberculosis transcriptome. Nature. 2024;627(8003):424-30. doi: 10.1038/s41586-024-07105-9, PMID 38418874
62. Qualls JE, Murray PJ. Immunometabolism within the tuberculosis granuloma: Amino acids, hypoxia, and cellular respiration. Semin Immunopathol. 2016;38(2):139-52. doi: 10.1007/s00281-015-0534-0, PMID 26490974
63. Nakiboneka R, Margaritella N, Nyirenda T, Chaima D, Walbaum N, Musisi E. Suppression of host gene expression is associated with latent TB infection: A possible diagnostic biomarker. Sci Rep. 2024;14(1):66486. doi: 10.1038/s41598-024-66486-z, PMID 38972907
64. Rustad TR, Harrell MI, Liao R, Sherman DR. The enduring hypoxic response of Mycobacterium tuberculosis. PLOS One. 2008;3(1):e1502. doi: 10.1371/journal.pone.0001502, PMID 18231589
65. Abebe G, Zegeye Bonsa WK. Treatment outcomes and associated factors in tuberculosis patients at Jimma University medical center: A 5-year retrospective study. Int J Mycobacteriol. 2017;6(3):239-45.
66. Jakkala K, Ajitkumar P. Hypoxic non-replicating persistent Mycobacterium tuberculosis develops thickened outer layer that helps in restricting rifampicin entry. Front Microbiol. 2019;10:2339. doi: 10.3389/fmicb.2019.02339, PMID 31681204
67. Velayati AA, Farnia P. Shape variation in Mycobacterium tuberculosis. Iran J Clin Infect Dis. 2011;6(2):95-101.
68. Campodónico VL, Rifat D, Chuang YM, Ioerger TR, Karakousis PC. Altered Mycobacterium tuberculosis cell wall metabolism and physiology associated with RpoB mutation H526D. Front Microbiol. 2018;9:494. doi: 10.3389/fmicb.2018.00494, PMID 29616007
69. Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol. 2008;69(1):164-74. doi: 10.1111/j.1365- 2958.2008.06274.x, PMID 18466296
70. McKinney JD, Höner Zu Bentrup K, Muñoz-Elias EJ, Miczak A, Chen B, Chan WT. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med. 2006;11(6):638-44.
71. Singh PR, Vijjamarri AK, Sarkar D. Metabolic switching of Mycobacterium tuberculosis during hypoxia is controlled by the virulence regulator PhoP. J Bacteriol. 2020;202(7):e00705-19.
72. Nambi S, Long JE, Mishra BB, Baker R, Murphy KC, Olive AJ. The oxidative stress network of Mycobacterium tuberculosis reveals coordination between radical detoxification systems. Cell Host Microbe. 2016;17(6):829-37.
73. Maurya RK, Bharti S, Krishnan MY. Triacylglycerols: Fuelling the hibernating Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2019;8:450.
74. Bi J, Wang Y, Yu H, Qian X, Wang H, Liu J. Modulation of central carbon metabolism by acetylation of isocitrate lyase in Mycobacterium tuberculosis. Sci Rep. 2017;7:44826. doi: 10.1038/ srep44826, PMID 28322251
75. Tang S, Hicks ND, Cheng YS, Silva A, Fortune SM, Sacchettini JC. Structural and functional insight into the Mycobacterium tuberculosis protein PrpR reveals a novel type of transcription factor. Nucleic Acids Res. 2019;47(18):9934-49. doi: 10.1093/nar/gkz724, PMID 31504787
76. Nastasi MR, Borisov VB, Forte E. Membrane-bound redox enzyme cytochrome bd-I promotes carbon monoxide-resistant Escherichia coli growth and respiration. Int J Mol Sci. 2024;25(2):1277. doi: 10.3390/ ijms25021277, PMID 38279276
77. Rao MJ, Duan M, Zhou C, Jiao J, Cheng P, Yang L. Antioxidant defense system in plants: Reactive oxygen species production, signaling, and scavenging during abiotic stress-induced oxidative damage. Horticulturae. 2025;11(5):477. doi: 10.3390/horticulturae11050477
78. Kunota TT, Rahman MA, Truebody BE, Mackenzie JS, Saini V, Lamprecht DA. Mycobacterium tuberculosis H2S functions as a sink to modulate central metabolism, bioenergetics, and drug
susceptibility. Antioxidants (Basel). 2021;10(8):1285. doi: 10.3390/ antiox10081285, PMID 34439535
79. Deb C, Lee CM, Dubey VS, Daniel J, Abomoelak B, Sirakova TD. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One. 2009;4(6):e6077. doi: 10.1371/journal.pone.0006077, PMID 19562030
80. Farzaneh SS, Norouzi F, Fazeli H, Salehi M, Safari M, Esfahani BN. Novel mutation in efflux pump Rv1258c (Tap) gene in drug resistant clinical isolates of Mycobacterium tuberculosis in Iran. J Infect Dev Ctries. 2024;18(2):235-42.
81. Du P, Sohaskey CD, Shi L. Transcriptional and physiological changes during Mycobacterium tuberculosis reactivation from non-replicating persistence. Front Microbiol. 2016;7:1346. doi: 10.3389/ fmicb.2016.01346, PMID 27630619
82. Boshoff HI, Warner DF, Gold B. Editorial: Drug-resistant Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2023;13:1215294.
83. Zhang F, Cheng W. The mechanism of bacterial resistance and potential bacteriostatic strategies. Antibiotics (Basel). 2022;11(9):1215. doi: 10.3390/antibiotics11091215, PMID 36139994
84. Boldrin F, Provvedi R, Cioetto Mazzabò L, Segafreddo G, Manganelli R. Tolerance and persistence to drugs: A main challenge in the fight against Mycobacterium tuberculosis. Front Microbiol. 2020;11:1924. doi: 10.3389/fmicb.2020.01924, PMID 32983003
85. Torrey HL, Keren I, Via LE, Lee JS, Lewis K. High persister mutants in Mycobacterium tuberculosis. PLoS One. 2016;11(5):e0155127. doi: 10.1371/journal.pone.0155127, PMID 27176494
86. Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: A review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. 2018;73(5):1138-51. doi: 10.1093/jac/dkx506, PMID 29360989
87. Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. Antimicrob Agents Chemother. 2012;56(5):2223-30. doi: 10.1128/AAC.06288-11, PMID 22391538
88. Sarathy JP, Dartois V, Lee EJ. The role of transport mechanisms in Mycobacterium tuberculosis drug resistance and tolerance. Pharmaceuticals (Basel). 2012;5(11):1210-35. doi: 10.3390/ph5111210, PMID 24281307
89. Piacenza L, Trujillo M, Radi R. Reactive species and pathogen antioxidant networks during phagocytosis. J Exp Med. 2019;216(3):501-16. doi: 10.1084/jem.20181886, PMID 30792185
90. Guo S, Chongsuvivatwong V, Lei S. Comparison on major gene mutations related to rifampicin and isoniazid resistance between Beijing and Non-Beijing strains of Mycobacterium tuberculosis: A systematic review and Bayesian meta-analysis. Genes (Basel). 2022;13(10):1849. doi: 10.3390/genes13101849, PMID 36292734
91. Zhou Y, Liao H, Pei L, Pu Y. Combatting persister cells: The daunting task in post-antibiotics era. Cell Insight. 2023;2(4):100104. doi: 10.1016/j.cellin.2023.100104, PMID 37304393
92. Chawla M, Mishra S, Anand K, Parikh P, Mehta M, Vij M. Redox-dependent condensation of the mycobacterial nucleoid by WhiB4. Redox Biol. 2018;19:116-33. doi: 10.1016/j.redox.2018.08.006, PMID 30149290
93. Jia L, Sha S, Yang S, Taj A, Ma Y. Effect of protein O-mannosyltransferase (MSMEG_5447) on M. Smegmatis and its survival in macrophages. Front Microbiol. 2021;12:657726.
94. Lee YV, Wahab HA, Choong YS. Potential inhibitors for isocitrate lyase of Mycobacterium tuberculosis and non-M. Tuberculosis: A summary. BioMed Res Int. 2015;2015:895453. doi: 10.1155/2015/895453, PMID 25649791
95. Vieira TF, Martins FG, Moreira JP, Barbosa T, Sousa SF. In silico identification of possible inhibitors for protein kinase B (PknB) of Mycobacterium tuberculosis. Molecules. 2021;26(20):6162. doi: 10.3390/molecules26206162, PMID 34684743
96. Abdelhamid AG, Yousef AE. Combating bacterial biofilms: Current and emerging antibiofilm strategies for treating persistent infections. Antibiotics (Basel). 2023;12(6):1005. doi: 10.3390/ antibiotics12061005, PMID 37370324
97. Lee JJ, Lim J, Gao S, Lawson CP, Odell M, Raheem S. Glutamate mediated metabolic neutralization mitigates propionate toxicity in intracellular Mycobacterium tuberculosis. Sci Rep. 2018;8(1):8506. doi: 10.1038/s41598-018-26950-z, PMID 29855554
98. Hillion M, Bernhardt J, Busche T, Rossius M, Maaß S, Becher D. Monitoring global protein thiol-oxidation and protein S-mycothiolation in Mycobacterium smegmatis under hypochlorite stress. Sci Rep. 2017;7:1195.
99. Singh S, Sharma N, Singh U, Singh T, Mangal DK, Singh V. Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID-19? Lung India. 2018;35(1):41-6.
100. Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: Challenges and priorities. Nat Rev Microbiol. 2022;20(11):685-701. doi: 10.1038/s41579-022-00731-y, PMID 35478222
101. Kim H, Shin SJ. Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism. Cell Mol Life Sci. 2023;80(10):291. doi: 10.1007/ s00018-023-04914-5, PMID 37704889
102. Prisic S, Husson RN. Mycobacterium tuberculosis serine/threonine protein kinases. Mol Genet Mycobact. 2015;2(5):681-708.
103. Zaporojan N, Hodișan R, Pantiș C, Csep AN, Zaporojan C, Zaha DC. Genotypic and phenotypic methods in the detection of MDR-TB and evolution to XDR-TB. Antibiotics (Basel). 2025;14(7):732. doi: 10.3390/antibiotics14070732, PMID 40724033
104. Gupta A, Prakash P, Singh SK, Anupurba S. Rapid genotypic detection of rpoB and katG gene mutations in Mycobacterium tuberculosis clinical isolates from Northern India as determined by MAS-PCR. J Clin Lab Anal. 2013;27(1):31-7. doi: 10.1002/jcla.21558, PMID 23325741
105. Reis RS, Neves I Jr., Lourenço SL, Fonseca LS, Lourenço MC. Comparison of flow cytometric and Alamar Blue tests with the proportional method for testing susceptibility of Mycobacterium tuberculosis to rifampin and isoniazid. J Clin Microbiol. 2004;42(5):2247-8. doi: 10.1128/JCM.42.5.2247-2248.2004, PMID 15131202
106. Lougheed KE, Osborne SA, Saxty B, Whalley D, Chapman T, Bouloc N. Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents. Tuberculosis (Edinb). 2011;91(4):277-86. doi: 10.1016/j.tube.2011.03.005, PMID 21482481
107. Olive AJ. Strategies and protective immunity during Mycobacterium tuberculosis infection. mSphere. 2025;e00517-24.
108. Striebel F, Imkamp F, Özcelik D, Weber-Ban E. Pupylation as a signal for proteasomal degradation in bacteria. Biochim Biophys Acta. 2014;1843(1):103-13. doi: 10.1016/j.bbamcr.2013.03.022, PMID 23557784
109. Mueller SS. Antibiotic resistance mechanisms in M. Tuberculosis. Physiol Behav. 2018;176(1):139-48.
110. Jeong EK, Lee HJ, Jung YJ. Host-directed therapies for tuberculosis. Pathogens. 2022;11(11):1291.
111. Tian N, Chu H, Li Q, Sun H, Zhang J, Chu N. Hosts-directed therapy for tuberculosis. Identifying clusters of raters with a common notion of diagnosing erosive tooth wear: A step towards improving the accuracy of diagnostic procedures. Eur J Med Res. 2025;30(1):15. doi: 10.1186/ s40001-024-02260-1, PMID 39780271
112. Kumar A, Farhana A, Guidry L, Saini V, Hondalus M, Steyn AJ. Redox homeostasis in mycobacteria: The key to tuberculosis control? Expert Rev Mol Med. 2011;13:e39. doi: 10.1017/S1462399411002079, PMID 22172201
113. Gholap AD, Khuspe PR, Pardeshi SR, Uddin MJ, Das U, Hatvate NT. Achieving optimal health with host-directed therapies (HDTs) in infectious diseases-a new horizon. Adv Ther. 2025;8(4):321-45. doi: 10.1002/adtp.202400169
114. Beites T, O’Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J. Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nat Commun. 2019;10(1):4970. doi: 10.1038/s41467-019-12956-2, PMID 31672993
115. Harikishore A, Grüber G. Mycobacterium tuberculosis F-ATP synthase inhibitors and targets. Antibiotics (Basel). 2024;13(12):1169. doi: 10.3390/antibiotics13121169, PMID 39766559
116. Stancil SL, Mirzayev F, Abdel-Rahman SM. Profiling pretomanid as a therapeutic option for TB infection: Evidence to date. Drug Des Devel Ther. 2021;15:2815-30. doi: 10.2147/DDDT.S281639, PMID 34234413
117. Lewis JM, Sloan DJ. The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag. 2015;11:779-91. doi: 10.2147/TCRM.S71076, PMID 25999726
118. Park JH, Shim D, Kim KE, Lee W, Shin SJ. Understanding metabolic regulation between host and pathogens: New opportunities for the development of improved therapeutic strategies against Mycobacterium tuberculosis infection. Front Cell Infect Microbiol. 2021;11:635335. doi: 10.3389/fcimb.2021.635335, PMID 33796480
119. Bigelow KM. Pharmacokinetics and pharmacodynamics of oxazolidinones and their contribution to a novel tuberculosis treatmentregimen. Clin Pharmacol. 2020 July;19:1-22.
120. Ramdhani D, Kusuma SA. In silico identification of natural products with antituberculosis activity for the inhibition of InhA and EthR proteins from Mycobacterium tuberculosis. Int J Appl Pharm. 2023;15(2):169-74. doi: 10.22159/ijap.2023.v15s2.31
121. Lata S, Khajuria V, Sawhney V, Kumari K. Evaluation of non-adherence to antitubercular drugs among tuberculosis patients: A prospective study. Int J Curr Pharm Res. 2021;13(2):26-8. doi: 10.22159/ijcpr.2021v13i2.41550
122. Odhar HA, Hashim AF, Ahjel SW, Humadi SS. Virtual screening of FDA-approved drugs by molecular docking and dynamics simulation to recognize potential inhibitors against Mycobacterium tuberculosis enoyl-acyl carrier protein reductase enzyme. Int J Appl Pharm. 2024;16(1):261-6. doi: 10.22159/ijap.2024v16i1.49471
123. Morales-Durán N, León-Buitimea A, Morones-Ramírez JR. Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions. Heliyon. 2024;10(6):e27984. doi: 10.1016/j.heliyon.2024.e27984, PMID 38510041
124. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature. 2011;469(7331):483-90. doi: 10.1038/nature09657, PMID 21270886
125. Cubillos-Angulo JM, Nogueira BM, Arriaga MB, Barreto-Duarte B, Araújo-Pereira M, Fernandes CD. Hosts-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs. Front Med (Lausanne). 2022;9:970408.
126. Naicker N, Sigal A, Naidoo K. Metformin as host-directed therapy for TB treatment: Scoping review. Front Microbiol. 2020;11:435. doi: 10.3389/fmicb.2020.00435, PMID 32411100
127. Mo L, Zhang W, Wang J, Weng XH, Chen S, Shao LY. Three-dimensional model and molecular mechanism of Mycobacterium tuberculosis catalase-peroxidase (KatG) and isoniazid-resistant KatG mutants. Microb Drug Resist. 2004;10(4):269-79. doi: 10.1089/ mdr.2004.10.269, PMID 15650370
128. El Zaatari M, Hashem MM, Lakkis RS, Abou Ghayda M, Al Shami J, Al Asmar S. Fatal case of disseminated tuberculosis in a 24 year-old male patient with Crohn’s disease: A case report. Int J Clin Res. 2020;1(1):1-14.
129. Amusengeri A, Khan A, Tastan Bishop Ö. The structural basis of Mycobacterium tuberculosis RpoB drug-resistant clinical mutations on rifampicin drug binding. Molecules. 2022;27(3):885. doi: 10.3390/ molecules27030885, PMID 35164151
130. Suryana K, Suharsono H, Joenputri N. The association between WHO clinical stage and other risk factors with pulmonary tuberculosis among people living with HIV/AIDS: A cross-sectional study. Int J Pharm Pharm Sci. 2020;12(7):18-22. doi: 10.22159/ijpps.2020v12i7.37982
131. Goossens SN, Sampson SL, Van Rie A. Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis. Clin Microbiol Rev. 2021;34(4):e00141-20.
132. Hameed HM, Islam MM, Chhotaray C, Wang C, Liu Y, Tan Y. Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis strains. Front Cell Infect Microbiol. 2018;8:114.
133. Bu Q, Qiang R, Fang L, Peng X, Zhang H, Cheng H. Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019. Front Pharmacol. 2023;14:1156249. doi: 10.3389/fphar.2023.1156249, PMID 36909179
134. Abramo JM, Reynolds A, Crisp GT, Weurlander M, Söderberg M, Scheja M. Individuality in music performance. Assess Eval High Educ. 2012 Oct;37:435.
135. Pule CM, Sampson SL, Warren RM, Black PA, Van Helden PD, Victor TC. Efflux pump inhibitors: Targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016;71(1):17-26. doi: 10.1093/jac/dkv316, PMID 26472768.
Published
How to Cite
Issue
Section
Copyright (c) 2026 MURALI KRISHNA KUMAR MUTHYALA
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.